APA (7th ed.) Citation

MG, I., A, P., E, A., RG, F., JM, L., DG, L., . . . D, D. (2025). Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): A multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine, 13(6), 517. https://doi.org/10.1016/S2213-2600(25)00048-7

Chicago Style (17th ed.) Citation

MG, Ison, et al. "Efficacy, Safety, and Immunogenicity of the AS01E-adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults over Three Respiratory Syncytial Virus Seasons (AReSVi-006): A Multicentre, Randomised, Observer-blinded, Placebo-controlled, Phase 3 Trial." The Lancet. Respiratory Medicine 13, no. 6 (2025): 517. https://doi.org/10.1016/S2213-2600(25)00048-7.

MLA (9th ed.) Citation

MG, Ison, et al. "Efficacy, Safety, and Immunogenicity of the AS01E-adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults over Three Respiratory Syncytial Virus Seasons (AReSVi-006): A Multicentre, Randomised, Observer-blinded, Placebo-controlled, Phase 3 Trial." The Lancet. Respiratory Medicine, vol. 13, no. 6, 2025, p. 517, https://doi.org/10.1016/S2213-2600(25)00048-7.